Moderna (MRNA) Operating Expenses (2017 - 2026)

Moderna (MRNA) has 10 years of Operating Expenses data on file, last reported at $1.8 billion in Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.8 billion, up 53.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 billion (down 18.38% YoY), and the FY2025 annual result was $5.0 billion, down 30.12% from the prior year.
• Operating Expenses advanced to $1.8 billion in Q1 2026 per MRNA's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $3.8 billion in Q3 2023 and troughed at $1.0 billion in Q2 2025.
• A 5-year average of $2.1 billion and a median of $1.9 billion in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses soared 174.07% in 2022, then tumbled 49.73% in 2024.
• A 5-year view of Operating Expenses shows it stood at $3.5 billion in 2022, then retreated by 19.95% to $2.8 billion in 2023, then retreated by 21.14% to $2.2 billion in 2024, then plunged by 30.61% to $1.5 billion in 2025, then grew by 15.77% to $1.8 billion in 2026.
• Business Quant data shows MRNA's Operating Expenses at $1.8 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.